![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MOCS1 |
Gene summary for MOCS1 |
![]() |
Gene information | Species | Human | Gene symbol | MOCS1 | Gene ID | 4337 |
Gene name | molybdenum cofactor synthesis 1 | |
Gene Alias | MIG11 | |
Cytomap | 6p21.2 | |
Gene Type | protein-coding | GO ID | GO:0006777 | UniProtAcc | A0A024RD17 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4337 | MOCS1 | HCC1_Meng | Human | Liver | HCC | 4.71e-29 | 4.14e-03 | 0.0246 |
4337 | MOCS1 | HCC1 | Human | Liver | HCC | 3.87e-05 | 1.60e+00 | 0.5336 |
4337 | MOCS1 | HCC2 | Human | Liver | HCC | 7.68e-12 | 4.00e+00 | 0.5341 |
4337 | MOCS1 | S014 | Human | Liver | HCC | 1.99e-03 | 2.05e-01 | 0.2254 |
4337 | MOCS1 | S015 | Human | Liver | HCC | 3.37e-03 | 2.33e-01 | 0.2375 |
4337 | MOCS1 | S016 | Human | Liver | HCC | 7.30e-03 | 1.87e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012402 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
hsa012403 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MOCS1 | SNV | Missense_Mutation | novel | c.567C>A | p.Phe189Leu | p.F189L | Q9NZB8 | protein_coding | tolerated(0.45) | benign(0.088) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MOCS1 | SNV | Missense_Mutation | c.70N>C | p.Ser24Pro | p.S24P | Q9NZB8 | protein_coding | tolerated(0.1) | benign(0.058) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MOCS1 | SNV | Missense_Mutation | novel | c.500T>C | p.Leu167Pro | p.L167P | Q9NZB8 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MOCS1 | SNV | Missense_Mutation | c.705G>C | p.Leu235Phe | p.L235F | Q9NZB8 | protein_coding | tolerated(0.21) | benign(0.045) | TCGA-C5-A2LX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
MOCS1 | SNV | Missense_Mutation | c.562N>C | p.Glu188Gln | p.E188Q | Q9NZB8 | protein_coding | tolerated(0.28) | possibly_damaging(0.858) | TCGA-EK-A2R7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
MOCS1 | SNV | Missense_Mutation | c.173C>T | p.Ser58Phe | p.S58F | Q9NZB8 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
MOCS1 | SNV | Missense_Mutation | c.887N>A | p.Gly296Asp | p.G296D | Q9NZB8 | protein_coding | tolerated(0.05) | benign(0.22) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
MOCS1 | SNV | Missense_Mutation | rs200517455 | c.331N>A | p.Ala111Thr | p.A111T | Q9NZB8 | protein_coding | deleterious(0.02) | probably_damaging(0.937) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MOCS1 | SNV | Missense_Mutation | novel | c.542N>T | p.Thr181Ile | p.T181I | Q9NZB8 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MOCS1 | SNV | Missense_Mutation | novel | c.401N>C | p.Asp134Ala | p.D134A | Q9NZB8 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4337 | MOCS1 | ENZYME | ALXN1101 |
Page: 1 |